CANTON, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the Nasdaq Hearings Panel and Nasdaq Listing Qualification Department have determined that the Company’s Class A common stock satisfies all applicable requirements for listing on The Nasdaq Stock Market, including the minimum 300 round lot shareholder requirement. This determination resolves the pending Nasdaq proceedings relating to the round lot holders of the Company’s Class A common stock.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
Press and Media Inquiries:
Angelyn Lowe
alowe@organo.com
781-774-9364
Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA
OrganoIR@westwicke.com
443-213-0500
Source: Organogenesis Holdings Inc.
